Arsenic trioxide (ATO) is an effective therapeutic agent against acute promyelocytic leukemia (APL); however, its anti-tumor effect on solid tumors such as colorectal cancer (CRC) is still in debate. Ascorbic acid (AA) also produces a selective cytotoxic activity against tumor cells. Here, we exploit the potential benefit of ATO/AA combination in generating cytotoxicity to CRC cells, which may lay the groundwork for the potential combinational chemotherapy of CRCs. According to the results, we found that ATO and AA effectively inhibited the viability of human CRC cells in a synergistic manner. AA and ATO corporately activated caspase-3 to trigger apoptosis and upregulated the expression of caspase-1 and promoted formation of inflammasomes to induce pyroptosis. Furthermore, the stimulation of reactive oxygen species (ROS) overproduction was demonstrated as a subcellular mechanism for apoptosis and pyroptosis induced by ATO/AA combination treatment. Our findings suggest that ATO combination with a conventional dosage of AA offers an advantage for killing CRC cells. The synergistic action of ATO/AA combination might be considered a plausible strategy for the treatment of CRC and perhaps other solid tumors as well.
INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the fourth leading cause of cancer-related deaths in the world (Arnold et al., 2017) . It is the third most frequent cancer in men after lung and prostate cancer, and is the third most frequent cancer in women after lung and breast cancer (Siegel et al., 2018) . Existing treatment options include surgery, radiation therapy, and chemotherapy, each with trade-offs between disease treatment and quality of life due to various side effects (Zerillo et al., 2017) . In particular, resistance to chemotherapy is intimately related to poor clinical outcomes. Arsenic compounds have been used for more than 2,400 years in treating a variety of ailments in both western and traditional Chinese medicines (Hughes, 2002) . In the 1970s, Zhang and colleagues first demonstrated the effectiveness of arsenic in curing acute promyelocytic leukemia (APL), a M3 subtype of acute myeloid leukemia (AML). Subsequent basic and clinical studies confirmed the efficacy of arsenic trioxide (ATO) in the treatment of APL. It has been reported that APL patients can achieve a complete alleviation with ATO with minimal side effects (Mathews et al., 2010) . Later on, ATO was found to induce apoptosis in several solid tumors such as in human lung, breast cancer cells, presumably via inducing overproduction of reactive oxygen species (ROS) (Waxman and Anderson, 2001; Pettersson et al., 2009; Martin-Martin et al., 2016 ); yet treatment with ATO alone did not benefit patients clinically (Subbarayan and Ardalan, 2014) . Moreover, the required doses of ATO increased the risk of side effects such as its cardiotoxicity, including long QT syndrome or torsade de pointes leading to sudden cardiac death (Chu et al., 2012) . Nonetheless, when combined with other agents, ATO can produce therapeutic benefits with governable toxicity. It is believed that high dose requirement and drug resistance cause failure of ATO treatment of solid tumors. Clearly, new strategies are needed to enhance the antitumor activity of ATO and/or to eliminate drug resistance while reducing the required dose of ATO to minimize its side effects.
Ascorbic acid (AA), also known as vitamin C, is often used as an antioxidant at low concentrations. Numerous studies, however, have uncovered its pro-oxidant activity at higher concentrations (De Laurenzi et al., 1995; Schwartz, 1996; Mandl et al., 2009; Vuyyuri et al., 2013) . Prominently, AA has found its therapeutic potential for cancers (McConnell and Herst, 2014) . A number of clinical trials have generated the data ascertaining the therapeutic value of AA in patients with terminal cancers (Cameron and Pauling, 1976; Moertel et al., 1985; Hoffer et al., 2008; Stephenson et al., 2013) . It has been proposed that AA can produce a selective cytotoxic activity against tumor cells without affecting normal cells (Xia et al., 2017) . Moreover, overwhelming reports have demonstrated that combinations of pharmacological AA with other anticancer agents can enhance cytotoxicity (Ma et al., 2014) .
Apoptosis (programmed cell death) is among the most common mechanisms for counteracting cancer cells or sensitizing cancer cells to chemotherapeutic agents and radiation therapy (Ghobrial et al., 2005) . ROS is known to be a strong apoptotic inducer involved in a variety of pathological processes (Chen et al., 2017) . The oxidative stress caused by ROS thus can be utilized as a novel cancer-damaging adjuvant (Ghobrial et al., 2005) . Many studies have indicated that agents interfering ROS metabolism can selectively eradicate the cancer cells by elevating the accumulation of ROS above a threshold of toxicity (Li et al., 2016) .
In addition to apoptosis, pyroptosis as another form of programmed cell death, is also believed to be one of the mechanisms for cancer cell death (Derangere et al., 2014) . Pyroptosis is lytic cell death initiated by inflammasomes, a process involving the activation of caspase-1 or caspase-11/4/5 to cleave gasdermin D (GSDMD) (He et al., 2015) . It has been proposed that pyroptosis can be utilized for cancer therapy (Wang et al., 2019) . Intriguingly, ROS can evoke the inflammasome-dependent pyroptosis in addition to induce apoptosis (Chen and Nunez, 2011; Lin and Zhang, 2017) .
We therefore set up the present study to exploit the feasibility of combination of ATO and AA for better anti-cancer efficacy and delineate the possible roles of apoptosis and pyroptosis in conferring the advantages to the combination over each of the single agents. Additionally, two kinds of CRC cells were employed to explore the anti-tumor efficacy of the combination of AA and ATO. Specifically, we investigated the potential facilitating effects of AA on the anti-tumor property of ATO in solid tumor cells or CRC cells or the synergistic effects of ATO/AA combination, and the underlying cellular mechanisms for the effects.
MATERIALS AND METHODS

Cell Culture and Reagents
Human SW620 colorectal adenocarcinoma (ATCC ® CCL-227™) and LOVO colorectal adenocarcinoma (ATCC ® CCL-229™) cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). LOVO cells were maintained in F-12K medium (SH30526.01; Hyclone, Utah, USA), supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution (Beyotime, Shanghai, China) at 37°C in 5% CO 2 . SW620 cells were cultured in L-15 medium (SH30525.01; Hyclone) containing 2 mM glutamine, 10% FBS, and 1% antibiotic-antimycotic solution with a humidified atmosphere containing 100% air at 37°C. FBS was purchased from BI (04-001-1A; BioInd, Kibbutz, Israel).
Cells were treated with varying concentrations of AA in combination with a concentration (2 mM) of ATO for 24 h to induce apoptosis. Only sub-confluent monolayers of cells (70% to 80%) were used in all experiments. Arsenious acid and sodium chloride injection was obtained from Harbin Medical University Pharmaceutical Co., Ltd (Harbin, China). AA was purchased from Sigma-Aldrich (A5960; USA) and dissolved in phosphatebuffered saline (PBS) buffer solution (SH30256.01B; Hyclone, USA). Tempol (2226-96-2; USA) and Z-VAD-FMK (187389-52-2; USA) were obtained from MedChemexpress (Monmouth Junction, NJ, USA). The antibodies against Bax (#5023), Bcl-2 (#2872), caspase-3 (#9662), cleaved-caspase-3 (#9662), and caspase-1 (#3866) were purchased from Cell Signaling Technology (Boston, Massachusetts, USA).
Cell Viability Assay
Cell viability was evaluated using the Cell Counting Kit-8 (CCK-8, LJ621; Dojindo, Japan) according to the manufacturer's instructions. Cells were seeded in 96-well flat bottom microtiter plates at a density of 5,000 cells per well. Cells were starved for 8 h and then treated with AA and ATO for 24 h. After drug treatment, cells were incubated with 10 ml CCK-8 solution for 1.5 h. The absorbance was measured at 450 nm on a microplate spectrophotometer (Tecan, Mannedorf, Switzerland).
Combination Index Analysis
The combination index (CI) of growth inhibition was calculated using the CompuSyn software (Biosoft, USA). The CI was calculated to determine the synergistic cytotoxicity according to the classic isobologram equation: CI = (D)1/(Dx)1 + (D)2/(Dx)2, where Dx is the concentration of one drug that produces the effect, and (D)1 and (D)2 are the concentrations of the two drugs in combination that produce the same effect. CI = 1 indicates an additive effect, CI < 1 indicates synergy, and CI > 1 reflects antagonism between two drugs. Combination studies were performed using the similar protocol as described in the previous study (Tan et al., 2019) . Briefly, the IC50 of ATO and AA was first determined in single drug experiments. Cells were then treated with increasing doses of ATO or AA at a non-constant-ratio combination of both drugs. The cell growth of single and combination drug experiments were determined after 24 h.
TdT-Mediated dUTP Nick-End Labeling Assay
TdT-mediated dUTP nick-end labeling (TUNEL) assay was performed in SW620 cells plated in 24-well chamber slides treated with either 2 mM AA or 2 mM ATO or combination of AA and ATO for 24 h. Cells were fixed in 4% methanol-free formaldehyde solution in PBS (25 min at 4°C), washed twice with PBS, permeabilized with 0.2% Triton X-100 (5 min), and rinsed twice with PBS. The SW620 cells were analyzed for apoptosis with TUNEL assay by using In Situ Cell Death Detection Kit (Cat. No. 11684817910; Roche, Mannheim, Germany) .The cells were incubated with TUNEL Reaction Mixture for 1 h at 37°C in the dark. After counterstaining with DAPI at room temperature for 10 min, analysis was performed using a fluorescence microscope (Zeiss, Jena, Germany). TUNEL-positive cells were stained in red within the nucleus. The assay was repeated five times.
Electron Microscopy
Cells were harvested and fixed in 2.5% glutaraldehyde (pH 7.4) overnight and then immersed in 0.1 M cacodylate buffer with 1% osmium tetroxide for 1 h. Samples were dehydrated with a concentration gradient of ethanol and then embedded in Epon medium and dissected into 60-70 nm sections. After being stained with uranylacetate and lead citrate, sections were examined under a JEOL 1200 electron microscope (JEOL Ltd., Tokyo, Japan).
Apoptosis Assay
The Annexin V-FITC apoptosis detection kit purchased from Beyotime Biotechnology was applied to detect cell apoptosis. SW620 cells (5.0 × 10 5 /1 ml) in logarithmic phase were treated with different drugs for 24 h. The treated cells were collected and washed with cold PBS after treatment. In accordance with the manufacturer's instructions, the cells were stained with Annexin V-FITC and propidium iodide for 20 min at room temperature in the dark, and the apoptosis rate of the treated cells was determined immediately after staining by CytoFlex Flow cytometry (CytoFLEXS; Beckman Coulter, United States).
Acridine Orange/Ethidium Bromide Staining Assay
Acridine orange/ethidium bromide (AO/EB) apoptotic staining was used to detect the morphology of apoptotic cells. SW620 cells were plated into 24-well chamber slides treated with either AA or ATO or combination of AA and ATO for 24 h. Then the cells were washed three times in PBS at room temperature, and then mixed with 1 ml of dye mixture containing 100 mg/ml AO and 100 mg/ml EB (CA1140; Solarbio, China) in PBS for 5 min. Cellular morphological changes was visualized immediately using a fluorescence microscope (Zeiss, Jena, Germany). Viable cells stained only by AO appeared bright green with intact structure, whereas apoptotic cells were stained orange with fragmented chromatin. And necrotic cells were stained red with condensation of chromatin by EB.
Clonogenic Assay
The clonogenic assay was used for accessing the proliferation of SW620 cells after treating with ATO, AA, and ATO/AA combination. For clonogenic assay, after 24 h of ATO, AA, and ATO/AA combination treatment, single cell suspension of 1,000 cells were plated in 20-mm dishes. Then the dishes were incubated in a 5% CO2 incubator at 37°C for 15 days. At day 15 after the colonies were formed, each dishes was washed in PBS and fixed with 4% paraformaldehyde at room temperature for 5 min. Then, the colonies were stained with 0.5% crystal violet for 30 min, washed, dried, and imaged. The number of colonies containing more than 50 cells were counted and calculated under a light microscope and used as an index for clonogenicity. The quantification of colony was determined by using Image J software. Each experiment was performed in triplicate.
Determination of ROS Generation
Intracellular ROS was detected by means of an oxidationsensitive dihydroethidium (DHE) fluorescent probe (Beyotime Biotechnology) using fluorescence microscope. After treatment with ATO (2 mM) and/or AA (2 mM), with or without Tempol (1 mM) for 24 h, cells were washed twice in PBS. Following treatment, floating and adherent cells were harvested, and they were then incubated with 10 mM DHE at 37°C for 20 min according to the manufacturer's instructions. Then analysis was performed using a fluorescence microscope (Zeiss, Jena, Germany) to detect intracellular ROS levels. We also used flow cytometry to detect intracellular ROS levels. After treatment, floating, and harvesting cells, 10 mM DCFH-DA (Beyotime Biotechnology) was added to the cells and the cells were further incubated for 60 min. DCFH-DA was deacetylated intracellularly by nonspecific esterase, which was further oxidized by ROS to the fluorescent compound 2,7dichlorofluorescein (DCF). DCF fluorescence distribution of 20,000 cells was detected by CytoFlex Flow cytometry (CytoFLEXS; Beckman Coulter, United States) at an excitation wavelength of 488 nm and an emission wavelength of 535 nm. Interleukin (IL)-18: forward 5′-CTTCCAGATCGCTTCCTCTC-3′ and reverse 5′-TCAAATAGAGGCCGATTTCC-3′. IL-1b: forward 5′-TTTGAGTCTGCCCAGTTCCC-3′ and reverse 5′-TCAGTTATATCCTGGCCGCC-3′. GAPDH: forward 5′-GAAGGTGAAGGTCGGAGTCA-3′ and reverse 5′-AATGAAGGGGTCATTGATGG-3′.
Statistical Analysis
Data are presented as mean ± standard error ofthe mean (SEM) for three independent experiments. Comparisons of mean values were performed with one-way ANOVA followed by the Tukey procedure. P < 0.05 was considered statistically significant. Statistical analysis was performed using Prism 7.0c GraphPad Software (GraphPad, San Diego, CA, United States).
RESULTS
AA Enhances the Cytotoxicity of ATO in CRC Cells
First, we evaluated the effects of ATO or AA alone on the viability of CRC cell lines using CCK-8 assay. We observed that ATO at concentrations ≥6 mM and AA ≥3 mM significantly decreased the number of living LOVO cells ( Figures 1A, B ).
Addition of ATO to culture medium in the presence of 2 mM AA facilitated the inhibitory effect of AA on cell viability in a concentration-dependent fashion ( Figure 1C ). Vice versa, the inhibitory effect of ATO on viability of LOVO cells was also markedly enhanced by addition of AA in dose-dependent manner ( Figure 1D ). Qualitatively the same results were consistently observed with either ATO or AA alone or combination of the two (Figures 1E-H) . These findings indicate the mutual facilitating effects or synergistic actions between ATO and AA in terms of their ability to induce cytotoxicity to CRC cells. In order to further confirm the synergistic actions of ATO combined with AA, we conducted CI analysis. Dose-effect analysis of the combination treatment was carried out based on the method of Chou-Talalay and the type of interaction between the two agents was evaluated using the CI (Chou, 2006) . According to the predictive calculation based on the CompuSyn software, the results revealed that both ATO and AA killed LOVO cells in a concentration-dependent manner, with the half inhibitory doses (IC50) for ATO and AA being 11.4 mM and 7.7 mM for 24 h of incubation, respectively. Then low and non-toxic doses of AA (2 mM) were selected to be tested with various doses of ATO in the combination treatments. As shown in Table 1 , the calculated CI values obtained were 0.44-0.53 for LOVO cells at 40-53% fractions affected. In addition, ATO concentration fixed at 2 mM in combination with increasing concentrations of AA for 24 h was used on LOVO cells. The results demonstrated that synergy between ATO and AA is moderate with CI = 0.43-0.66 for fa = 0.2-0.46 (Table 1) . Additionally, the IC50 values in SW620 cells treated with ATO for 24 h was 13.3 mM and those of AA was 24.7 mM based on the predictive calculation in the CompuSyn software. The values of CI for combination treatment calculated in Table 2 indicated that the significantly synergetic anti-cancer activity for combination treatment of AA and ATO in SW620 cells. To investigate the mechanism of the synergistic effect, we selected the combinations with 2 mM AA and 2 mM ATO in SW620 cells.
ATO/AA Combination Decreases CRC Viability Partly by Inducing Apoptosis
To elucidate whether the observed decreases in cell viability by ATO and AA are attributable to apoptotic cell death, we employed TUNEL staining to quantify DNA fragmentation. As depicted in Figure 2A , neither 2 mM ATO nor 2 mM AA induced apoptosis. However, the combination of the two compounds produced a remarkable pro-apoptotic effect. As depicted in Figure 2B , the single drug treatment did not increase the proportion of early and late apoptosis in SW620 cells. Furthermore, the combination of 2 mM ATO and 2 mM AA was found to more potently induce apoptosis in comparison to the single treatment. Similar results were obtained by morphological examination under an electron microscope ( Figure 2C) . Moreover, AO/EB staining indicated that apoptosis was markedly promoted in the combination of 2 mM ATO and 2 mM AA treated cells in compare with the single drug ATO or AA treatment ( Figure 2D) . Moreover, clonogenic assay demonstrated that ATO (2 mM) and AA (2 mM) combined application can significantly suppress the colony-forming activity of SW620 cells (Figure 2E) .
To further elaborate whether the apoptotic cell death induced by ATO and AA is mediated by the mitochondrial death pathway, we determined the expression of anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bax using Western blot analysis. As illustrated in Figure 2F , 2 mM ATO or 2 mM AA produced minimal effects on the protein levels of Bcl-2 and Bax. However, when co-applied, ATO (2 mM) and AA (2 mM) caused a substantial upregulation of Bax and concordant downregulation of Bcl-2 in SW620 cells. Moreover, the combination also synergistically increased the level of the cleaved or activated form of caspase-3, the executioner of apoptotic cell death ( Figure 2G) . Furthermore, exposure of SW620 cells to Z-VAD-FMK (a pan-caspase inhibitor) abrogated the suppressive effect of ATO/AA combination on cell viability ( Figure 2H ).
ATO/AA Combination Decreases CRC Viability Partly by Inducing Pyroptosis
Pyroptosis is recognized as a new type of inflammatory programed cell-death, which is typically initiated by the binding of intracellular pathogen to NOD-like receptors (NLRs), leading to the formation of inflammasomes. Inflammasomes can subsequently cause release of the active forms of the pro-inflammatory cytokines IL-1b and IL-18 to activate caspase-1 which executes cell death (Miao et al., 2010) . The electron microscope images shown in Figure 3A displayed the characteristic morphological features of pyroptosis, as evidenced by swelling and nuclear shrinkage of SW620 cells after treatment with ATO/AA combination, but not with ATO or AA alone. Consistently, the level of caspase-1 protein was significantly increased by the combination ( Figure  3B) . Meanwhile, the mRNA levels of pro-inflammatory cytokines IL-1b and IL-18, the pyroptosis-related genes, were also significantly upregulated by ATO and AA combination (Figures 3C, D) .
ATO/AA Combination Synergistically Produces Pro-Apoptotic Effects by Stimulating ROS Generation
Previous studies have established that ROS produced through the oxidation of AA is a crucial mediator of AA-induced cytotoxicity (Gong et al., 2016) . Similarly, ROS production to induce oxidative stress is also the primary mechanism by which ATO causes apoptosis of tumor cells (Baysan et al., 2007) . To elaborate if the observed synergistic effects of ATO and AA in inducing apoptosis of CRC cells could be ascribed to their ability to stimulate ROS production and accumulation, we measured the changes of ROS contents under varying conditions. As illustrated in Figure 4A , AA/ATO combination increases ROS levels by flow cytometry. Similar results were obtained with fluorescence staining of ROS ( Figure 4B) . Tempol, which is a stable piperidine nitroxide of low molecular weight, can easily permeates biological membranes and accumulates in the cytosol. Tempol could act as an intracellular scavenger of superoxide anions, particularly, hydroxyl radicals (Wilcox, 2010) . Tempol specifically targets mitochondrial ROS. Mariappan et al. demonstrated that tempol prevented O2 − production by mitochondrial complex 1 when tumor necrosis factor alpha was administered (Mariappan et al., 2009 ). It has also been shown to prevent angiotensin II from stimulating mitochondrial ROS (Kimura et al., 2005) . In addition, the suppressing effects of ATO and AA on cell viability was significantly mitigated by tempol, a ROS inhibitor ( Figure 4C) . Consistently, tempol also prevented the upregulation of Bax and downregulation of Bcl-2 induced by ATO/AA combination ( Figure 4D) , as well as the increase in cleaved caspase-3 level in SW620 cells ( Figure 4E ).
ATO/AA Combination Synergistically
Produces Pro-Pyroptotic Effects by Stimulating ROS Generation
As already described above, ATO/AA combination synergistically elevated the protein level of caspase-1 and the mRNA levels of IL-1b and IL-18 as well ( Figures 3B-D) . In order to verify that ROS underlies at least partly the observed effects, we went on to evaluate the influence of tempol on the effects of ATO/AA combination. As depicted in Figure 5 , exposure of SW620 cells to tempol pronouncedly abrogated the upregulation of caspase-1 protein ( Figure 5A ) and IL-1b and IL-18 mRNAs induced by ATO/AA combination ( Figures 5B, C) .
DISCUSSION
The findings of our present study indicate that the synergistic interaction between AA and ATO in CRC cells. AA significantly potentiates the effect of ATO on cell death of CRC and vice versa. This interaction facilitates ROS production in CRC cells to induce apoptosis and pyroptosis. ATO has been clinically recommended as a potent antileukemic agent for clinical therapy of complete remission in patients with refractory acute promyelocytic leukemia, a M3 subtype of AML (Soignet et al., 1998) . At clinically achievable concentrations of 1-2 mM ATO induces apoptosis in patients with APL with minimal side effects (Chen et al., 1996) . The cytotoxic effect of ATO on APL is thought to be mediated by its ability to induce oxidative stress. The median daily dose of ATO in a pilot study was 0.15 mg/kg (0.06-0.2 mg/kg), within the clinically relevant concentrations being 0.1-1.5 mM (Siu et al., 2006) .
We have previously demonstrated that only a high dose of ATO (> 2 mM) directly increases ROS production and induces apoptosis in myocytes (Zhao et al., 2008) . Overwhelming reports have suggested that ATO is not limited to the treatment of leukemia, but has also the potential to suppress solid tumors such as breast cancer, hepatocellular carcinoma, and CRC (Rollig and Illmer, 2009; Wang et al., 2014; Eyvani et al., 2016; Yoon et al., 2016; Shi et al., 2017) . The mechanism of ATO-induced apoptosis is mainly ascribed to ROS over-generation. Nevertheless, ATO can cause severe toxicities such as long QT syndrome/torsade de pointes and sudden cardiac death, which hampers the clinical applications of ATO to solid tumors (Li et al., 2013) .
On the other hand, clinical efficiency of anticancer drugs is frequently limited by emergence of various mechanisms of resistance in tumor cells (Vernhet et al., 2001) , and ATO has also been associated with a rapid development of clinical resistance in patients (Soignet et al., 1998) (Subbarayan et al., 2007) . In general, side effects and drug resistance due to high-dose applications partly account for the failure of single ATO treatment in solid tumors. Clearly, avoiding toxicity and eliminating drug resistance of ATO are critical and highly desirable for the applications of ATO to curing solid tumors. Given most of the solid tumors are believed to be hypoxic, solid tumors do not respond to arsenic. In addition, inner core of tumors lack blood vessels and therefore may not receive ATO. Thus, non-delivery of ATO to solid tumors may be a reason for the treatment failure (Subbarayan et al., 2007) . One way to tackle the issues is using conventional doses of ATO while keeping high therapeutic efficacy by adopting the approach of combinational drug applications.
AA functions primarily as an antioxidant and can protect cells from oxidative stress at lower concentrations. However, at higher concentrations AA acts as a pro-oxidant that imposes oxidative stress and induces cell death; It has been proposed to have cancer therapeutic potential (Verrax and Calderon, 2009 ). Chen et al. revealed that when administered at high doses in the millimolar (mM) range, AA behaves as a powerful pro-oxidant, generating hydrogen peroxide-dependent cytotoxicity toward a variety of cancer cells in vitro (Chen et al., 2007) . On the other hand, ATO is known to be a pro-oxidant via downregulating ROS scavenger proteins and disrupting redox pathways. We reasoned that ATO could interact with AA and produce synergistic effects against tumors. Indeed, AA has been shown to synergize the cytotoxic effects of ATO in several types of cancers, such as B-cell chronic lymphocytic leukemia, lymphoid malignancies, multiple myeloma, and pancreatic cancer (Chang et al., 2009; Biswas et al., 2010; Dinnen et al., 2013 ). Yet, the cytotoxicity effect of AA and ATO combination on colon cancer remains largely obscure. In the present study, we confirmed that AA could reinforce ATO-induced apoptosis by promoting ROS overproduction. Moreover, some clinicians have infused more than 10 g of ascorbate in cancer patients and achieved plasma concentrations of 1 to 5 mM, which showed survival benefit and symptomatic relief (Riordan et al., 1995) . In our research, we conducted 2 mM concentration of AA co-treated with 2 mM ATO, which mostly kills CRC cells by inducing cyto-apoptosis and pyroptosis via increasing intracellular ROS. In addition, vitamin C accumulates in solid tumors to concentrations higher than in surrounding normal tissue (Agus et al., 1999) . This phenomenon favors the positive outcome of high-dose intravenous vitamin C therapy in cancer patients. So our study may have clinical meaning for the survival benefit and symptomatic relief of cancer patients.
Pyroptosis is a form of lytic programmed cell death initiated by inflammasomes that activate caspase-1 followed by releasing pro-inflammatory factors IL-1b and IL-18. We show here for the first time that AA and ATO combination synergistically enhanced pyroptosis and the underlying mechanism is likely to promote overproduction and accumulation of intracellular ROS, FIGURE 6 | Cartoon presentation of proposed cellular and molecular mechanisms for the synergistic effects of ATO/AA combination treatment. AA and ATO enter the colorectal cancer cells and induce overproduction of ROS that in turn activates the mitochondrial apoptotic pathway with increased expression of Bax and caspase-3 and decreased expression of Bcl-2. On the other hand, AA and ATO activate pyroptosis signaling by increasing caspase-1 and releasing IL-1b and IL-18. AA sensitizes ATO-induced apoptosis and pyroptosis by ROS-dependent oxidative stress in colon cancer cells. Tian et al. AA/ATO Combination Inhibits CRC a critical inducer of the inflammasome-dependent pyroptosis (Zhou et al., 2018) . Interestingly, our results demonstrate that the combination of ATO and AA synergistically enhanced pyroptosis by stimulating ROS generation and upregulated the expression levels of IL-1beta and IL-18 mRNAs, whereas each of the two drugs downregulated the expression of the two cytokines ( Figures 3C, D; 5B, C) . The combination of ATO and AA synergistically upregulated the expression levels of IL-1beta and IL-18 mRNAs which were pro-inflammatory factors released by pyroptosis. Maier et al. indicated that ATO inhibited activation of the nucleotide-binding oligomerization domain-like receptor (NLR) proteins inflammasomes, preventing the autoproteolytic activation of caspase-1 and the processing and secretion of IL-1b from macrophages (Maier et al., 2014) . And several studies revealed that ATO markedly reduced IL-18, NO, TNF-a, and IL-10 levels in MRL/lpr mice developing human lupus-like syndrome and inhibited NF-kB expression and DNA binding in colon extracts, leading to decreased cytokine gene expression (e.g., TNF-a, IL-1b, IL-17, and IL-18) in a murine colitis model (Bobe et al., 2006; Singer et al., 2011) . However, ATO was found to induce apoptosis in several cancer cells via inducing ROS production. In agreement with previous results, the accumulation of ROS production may contribute to the upregulation of IL-1beta and IL-8 mRNAs. So we still need to explore whether there exists other mechanisms underlying that lead to the downregulation of the expression of the two cytokines by adding ATO/AA. Collectively, our results provide the first evidence that AA could sensitize ATO-induced pyroptosis by stimulating ROS production. Hence, pyroptosis is likely one of the cellular mechanisms underlying the cytotoxicity effect of AA and ATO on CRC. The role of ROS in mediating the enhanced cytotoxicity (apoptosis and pyroptosis) of AA/ATO combination against CRC cells was verified by the results exhibiting the effectiveness of ROS scavenger Tempol in mitigating the cytotoxicity of AA/ATO co-application.
Collectively, we present the evidence for the superiority of ATO/AA combination with a conventional dosage of ATO and AA for cancer therapy over ATO or AA alone at higher doses in the context of generating cytotoxicity against CRC cells. We also demonstrate that enhanced apoptosis and pyroptosis are likely a cellular mechanism for the synergistic action of ATO/AA combination. Furthermore, we provide evidence for ROS overproduction as a molecular/metabolic mechanism for the induction of apoptosis and pyroptosis by ATO/AA combination treatment ( Figure 6 ). Our findings therefore provide a rationale for ATO/AA combination as a plausible strategy for the treatment of CRC and other solid tumors as well.
